MADRIGAL PHARMACEUTICALS, INC. Increase (Decrease) in Inventories
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Increase (Decrease) in Inventories of $33.65 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-07-30
- MADRIGAL PHARMACEUTICALS, INC. increase (decrease) in inventories for the quarter ending 2026-06-30 was $11.46M, a 38.83% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. increase (decrease) in inventories for the quarter ending 2026-03-31 was $22.19M, a 4.79% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. increase (decrease) in inventories for the quarter ending 2025-12-31 was $1.73M, a 93.18% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. increase (decrease) in inventories for the quarter ending 2025-09-30 was $5.82M, a 254.23% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. increase (decrease) in inventories for fiscal 2025 was $36.98M, a 8.54% increase from fiscal 2024.
- MADRIGAL PHARMACEUTICALS, INC. increase (decrease) in inventories for fiscal 2024 was $34.07M.
- MADRIGAL PHARMACEUTICALS, INC. increase (decrease) in inventories for fiscal 2023 was $0.00.
- MADRIGAL PHARMACEUTICALS, INC. increase (decrease) in inventories for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $33.65M 10-Q · filed 2026-07-30 | $35.38M derived: sum of 3 quarters · filed 2026-07-30 | $41.20M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $22.19M 10-Q · filed 2026-05-06 | $23.92M derived: sum of 2 quarters · filed 2026-05-06 | $29.74M derived: sum of 3 quarters · filed 2026-05-06 | $37.99M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $7.55M derived: sum of 2 quarters · filed 2026-02-19 | $15.80M derived: sum of 3 quarters · filed 2026-07-30 | $36.98M 10-K · filed 2026-02-19 |
| 2025-09-30 | $5.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $14.08M derived: sum of 2 quarters · filed 2026-07-30 | $35.25M 10-Q · filed 2025-11-04 | $60.60M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $8.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $29.43M 10-Q · filed 2026-07-30 | $54.78M derived: sum of 3 quarters · filed 2026-07-30 | $56.42M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $21.17M 10-Q · filed 2026-05-06 | $46.53M derived: sum of 2 quarters · filed 2026-05-06 | $48.17M derived: sum of 3 quarters · filed 2026-05-06 | $54.39M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $25.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $27.00M derived: sum of 2 quarters · filed 2026-02-19 | $33.21M derived: sum of 3 quarters · filed 2026-02-19 | $34.07M 10-K · filed 2026-02-19 |
| 2024-09-30 | $1.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $7.86M derived: sum of 2 quarters · filed 2025-11-04 | $8.71M 10-Q · filed 2025-11-04 | $8.71M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $6.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $7.07M 10-Q · filed 2025-08-05 | $7.07M derived: sum of 3 quarters · filed 2026-02-19 | $7.07M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $854.00K 10-Q · filed 2025-05-01 | $854.00K derived: sum of 2 quarters · filed 2026-02-19 | $854.00K derived: sum of 3 quarters · filed 2026-02-19 | $854.00K derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $0.00 derived: sum of 3 quarters · filed 2026-02-19 | $0.00 10-K · filed 2026-02-19 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $0.00 derived: sum of 2 quarters · filed 2024-10-31 | $0.00 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |